Literature DB >> 2503999

Transformation of BCG with plasmid DNA.

L Lugosi1, W Jacobs, B R Bloom.   

Abstract

Pasteur 1173P2 and Japanese 172 BCG substrains were transformed with plasmid pAL5000::plJ666 by electroporation and assessed by the growth of kanamycin-resistant colonies. From the transformants pYUP plasmids were isolated containing plJ666 inserted into pAL5000. The introduction, persistence and the identity of the plasmid were monitored by reisolation from consecutive subcultures and restriction analysis. The effect of variables--age, viability, glycine pretreatment of BCG cultures, electroporation parameters--on transformation frequencies were analyzed. Consecutive transformation of BCG with plasmid DNA isolated from a BCG transformant increased the efficiency from the level of 10(1)-10(2) obtained with the initial library to 10(3)-10(4) colonies/micrograms DNA with the pYUB plasmids. Maintenance of plasmid and expression of kanamycin resistance in continuous subcultures were stable for 100 generations from the first successful transformation to the present. The introduction and stable expression of foreign DNA in BCG on a plasmid vector establishes a basis for the construction of polyvalent recombinant BCG vaccine vehicles expressing not only putative protective mycobacterial antigens, but also antigens for other infectious and malignant diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503999

Source DB:  PubMed          Journal:  Acta Leprol        ISSN: 0001-5938


  2 in total

1.  Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Authors:  Maximillian Rosario; Richard Hopkins; John Fulkerson; Nicola Borthwick; Máire F Quigley; Joan Joseph; Daniel C Douek; Hui Yee Greenaway; Vanessa Venturi; Emma Gostick; David A Price; Gerald W Both; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

2.  Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Authors:  Richard Hopkins; Anne Bridgeman; Joan Joseph; Sarah C Gilbert; Helen McShane; Tomáš Hanke
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.